EHA 2022: Dose Response Profile of IGM-2323, a CD20xCD3 IgM Bispecific T Cell Engager, in Translational Models Supports Phase 2 Dose Selection in Non-Hodgkin’s Lymphoma

European Hematology Association 2022 Hybrid Congress – June 9-12, 2022